Immunyx selected as a Quick Fire Challenge Project Nextgen Recipient

September 2023

The Biomedical Advanced Research and Development Authority (BARDA) and Johnson & Johnson Innovation are thrilled to announce...

Immunyx selected as a BlueKnight Company

January 2023

Immunyx Pharma, a developer of immune modulating therapies for neutrophil based diseases, announced it has been selected...

Targeted nanoparticles modify neutrophil function in vivo

October 2022

Neutrophils play critical roles in a broad spectrum of clinical conditions. Accordingly, manipulation of neutrophil...

Hero image immunyX

Contact Us

Immunyx strives to improve disease treatment. If you’re interested in our mission we would love to hear from you.